AXONHIGH SIGNALFINANCIAL10-K

Axon's financial profile shows significant balance sheet expansion alongside substantially reduced profitability and operating cash flow generation.

The company appears to be in a major investment phase, with R&D spending meaningfully higher and capital expenditures substantially increased, but this is coming at the cost of current profitability and cash generation. The near-doubling of total liabilities alongside expanded current assets suggests either significant debt financing or operational scaling that investors should monitor closely.

Comparing 2026-02-25 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

Axon's balance sheet expanded dramatically with total assets growing 56% and total liabilities increasing 75%, indicating significant capital deployment or financing activity. However, operational performance deteriorated meaningfully with net income substantially reduced and operating cash flow declining by nearly half. The combination of substantially higher R&D spending and increased capital expenditures suggests heavy investment in growth initiatives, but the sharp decline in cash generation raises questions about the near-term return on this capital deployment.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+75%
$2.1B→$3.8B

Liabilities grew 75% — significant increase in debt or obligations, assess impact on financial flexibility.

Capital Expenditure
Cash Flow
+72.9%
$78.8M→$136.3M

Capital expenditure jumped 72.9% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-66.9%
$377.0M→$124.7M

Net income declined 66.9% — review whether driven by operations, interest costs, or non-recurring items.

Current Assets
Balance Sheet
+61.6%
$2.3B→$3.7B

Current assets grew 61.6% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+56.4%
$4.5B→$7.0B

Asset base grew 56.4% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
+55%
$441.6M→$684.3M

R&D investment increased 55% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
+53.7%
$11.8M→$18.1M

Receivables surged 53.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-48.2%
$408.3M→$211.3M

Operating cash flow fell 48.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
+47.4%
$997.6M→$1.5B

Current liabilities surged 47.4% — significant near-term obligations; verify ability to meet short-term debt.

SG&A Expense
P&L
+39.8%
$741.2M→$1.0B

SG&A up 39.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-28
ADDED
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 38 Item 6 .
Management s Discussion and Analysis of Financial Condition and Results of Operations 40 Item 7A .
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 107 Item 9 A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 110 Item 1 3 .
Certain Relationships and Related Transactions, and Director Independence 110 Item 1 4 .
( Axon, the Company, we or us ) is a technology company that provides integrated hardware and software solutions.
Founder-led since 1993, Axon began with a mission to protect life and has grown into a global technology company serving a range of customers.
Our products and services allow customers across the public and private sector to capture and use critical data to support fully-connected operational workflows.
Our trusted network seamlessly integrates software and hardware with a range of connected devices, including TASER energy devices, cameras and sensors, drones and robotics, cloud-based evidence management, records management, real-time operations software, critical incident and emergency response systems, immersive training, and productivity tools all enhanced by artificial intelligence ( AI ).
Designed to work together, these solutions create a unified, data-driven operating system that prioritizes safety and helps protect people and places with greater speed, accuracy, transparency, and accountability.
REMOVED
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 41 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 43 Item 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 112 Item 9A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 115 Item 13.
( Axon, the Company, we or us ) is a technology leader in global public safety.
In 2022, we announced our moonshot goal to cut gun-related deaths between police and the public in the United States in half by 2033.
Axon is building the public safety operating system of the future by integrating a suite of hardware devices and cloud software solutions that not only revolutionize modern policing but also cater to federal agencies, corrections, justice and enterprise-level security needs.
Axon s suite includes cloud-hosted digital evidence management solutions, productivity and real-time operations software, body cameras, in-car cameras, TASER energy devices, drone and robotic security, and training solutions.
Our hardware and software solutions advance our mission to (i) make the bullet obsolete, (ii) reduce social conflict, and (iii) enable a fair and effective justice system.
Our products solve some of society's most challenging problems and our mission attracts top talent.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →